alveofit is a healthtech startup based in Pune, India, that offers a technology-enabled ecosystem for accessible and affordable respiratory care.

This Startup Deep Dive explains what alveofit does, how it makes money, who backs it, how it compares with rivals and what could go wrong, using publicly available information. It is educational and not investment advice. Last updated: October 2026.

alveofit in Brief

• What it is: alveofit is an Indian Respiratory care healthtech company based in Pune.
• Who it serves: patients, doctors, hospitals, diagnostic centres, insurers and employers.
• alveofit (legal name Roundworks Technologies Private Limited) builds a technology-enabled ecosystem for accessible and affordable respiratory care.
• Its main product is alveoair, a portable IoT handheld digital spirometer for patients with asthma, COPD, cystic fibrosis or interstitial lung disease.
• Companion apps include the alveofit patient app and the alveoMD provider app, with a SaaS platform for care management and remote tracking.
• Funding: $200K angel round (one database); another lists about $274K across 2 rounds including a small April 2022 round (reports differ).

alveofit Quick Facts

Figures marked “reported” come from published reports and may differ between sources; “Not disclosed” means no reliable public figure was found.

What Is alveofit?

alveofit operates in the Respiratory care healthtech space in India. Understanding a company like this starts with three questions: who is the customer, what painful problem is being solved, and why the solution is better than the alternatives. The sections below apply that lens to alveofit.

• alveofit (legal name Roundworks Technologies Private Limited) builds a technology-enabled ecosystem for accessible and affordable respiratory care.
• Its main product is alveoair, a portable IoT handheld digital spirometer for patients with asthma, COPD, cystic fibrosis or interstitial lung disease.
• Companion apps include the alveofit patient app and the alveoMD provider app, with a SaaS platform for care management and remote tracking.
• The company is developing AI-based predictive analytics so clinicians can prioritise cases.

The Origin Story of alveofit

Every company starts from a noticed gap and a team willing to commit to closing it. Strong origin stories are specific: a clear problem, a founding team with relevant skills, and an early product that real customers could test. Founder-market fit, meaning the team’s lived experience or technical depth in the domain, tends to predict how fast a young company learns.

• Founders: Devendra Prasad, Prashant Patel.
• Listed as founded in 2019 in Pune by Devendra Prasad and Prashant Patel (startup database); Dr Prashant Patel is quoted by the company on the product's purpose.
• The company is a DST-backed startup profiled in India's science and technology startup technologies listing.

Key Milestones and Challenges

No startup grows in a straight line. Early years usually involve slow adoption, product rewrites, hiring mistakes and funding gaps. In the Respiratory care healthtech sector the common turning points are a first paying customer, a regulatory approval, a successful product demonstration or a funding round that lets the team invest ahead of demand. How a team responds to setbacks says more about resilience than any single headline.

• 2019: founded in Pune.
• June 2021: $200K angel round led by Forge Innovation and Ventures.
• June 2022: CDSCO certification in India for alveoair.
• August 2022: AstraZeneca India partnership announced to supply IoT spirometers to clinics and last-mile hospitals; pilot tested over 2,800 patients with about 35-40% diagnosed with lung issues.
• 2023: opened a New York office.
• September 2023: alveoair received US FDA clearance, described as India's first such FDA-cleared device of its kind.

alveofit Funding and Investors

Funding history shows how much outside confidence a company has attracted and how long it can operate before needing more capital. Figures below are reported and may differ between sources; valuation figures are estimates unless the company has confirmed them.

• Angel round, 18-19 June 2021, $200K, led by Forge Innovation and Ventures (reported).

How Does alveofit Make Money? (Business Model)

A business model describes who pays, how often and how much it costs to serve them. Strong models show repeat usage, improving margins with scale and acquisition channels that do not depend only on paid spend. Weak models show one-off sales, rising costs and growth that stops when spending stops. For companies selling to patients, doctors, hospitals, diagnostic centres, insurers and employers, sales cycles and contract size matter as much as headline growth.

• Sells spirometer devices plus SaaS and app subscriptions to hospitals, clinics and care providers.
• Partner-led distribution: AstraZeneca supplied devices to hospitals; Tatvacare alliance extends care to patients' homes.
• Expansion into the US and emerging economies after FDA clearance.

The Numbers: alveofit Financials

Financial figures show whether growth is turning into a self-sustaining business. Small and private companies often disclose little, so any number below is included only if it was found in public reporting.

• FY23 revenue about Rs 30.5 lakh, up about 1,656% on the prior year (reported by a database).
• Adopted by more than 400 healthcare facilities in India since CDSCO certification (company-stated).
• About 24 employees (database).

Market Opportunity for alveofit

Market size is easy to exaggerate, so a useful approach separates the total market from the portion a company can realistically reach with its current product and distribution. The main forces behind demand in this sector are rising chronic disease, growing health insurance penetration, government programmes such as Ayushman Bharat and the Ayushman Bharat Digital Mission, and the shift of care to digital and home settings. Each of these widens the opportunity, but capital efficiency and execution decide who captures it.

• Respiratory disease burden in India (asthma, COPD, post-COVID lung problems and pollution) drives demand for early spirometry testing (stated in partnership coverage).
• Plans to extend deployments to tier-2 and tier-3 towns.

Technology and Product at alveofit

Technology is rarely the whole moat, but it drives speed, cost and customer experience. A practical way to assess it is to separate the capability the company controls from the commodity infrastructure it rents. In this sector the important factors are clinical validity, data quality, integration with hospital and lab systems, and trust among doctors and patients.

• IoT-enabled portable digital spirometer with real-time data sharing to clinicians.
• AI-based predictive analytics in development; telespirometry for remote monitoring.

Team and Culture at alveofit

Teams are the most important and least measurable asset of a young company. Look at how complementary the founders’ skills are, how deep the second layer of leadership is, and how the company hires and retains specialists. Culture shows up in small repeated behaviours: how quickly bad news travels upward and whether commitments to customers are kept.

• Founders Devendra Prasad and Prashant Patel per a startup database; Dr Patel is the voice quoted in company announcements.
• Partners include AstraZeneca, AIIMS Delhi (clinical research), Tatvacare, PATH (spirometry project in Satara), NASSCOM COE and India Sweden Innovation Centre.

alveofit Competitors: Competitive Landscape

A fair competitive analysis names direct rivals, adjacent players who could move into the space, and the customer’s default alternative. Durable advantages include proprietary data or technology, licences and approvals, brand trust, switching costs and cost leadership.

Risks and Challenges for alveofit

• Small revenue base and no newer disclosed funding round beyond tiny angel money.
• Dependence on partner-led deployments such as AstraZeneca for growth.
• Regulatory risk: medical devices, diagnostics, online pharmacy and telemedicine each face different and changing rules.
• Clinical and liability risk: errors in care, diagnosis or product quality can damage trust quickly.
• Data privacy risk: health records are sensitive, and breaches or misuse can bring legal and reputational harm.

Risk is not a reason to avoid a company; it is a reason to price it correctly and to monitor the right indicators over time. Regulation in this sector is shaped by the CDSCO, state health regulators, the National Medical Commission and the Digital Personal Data Protection Act.

alveofit Growth Outlook: What to Watch

• Plans to expand in the US and emerging economies and to scale across India including tier-2 and tier-3 towns.
• Developing AI predictive analytics for respiratory health (company-stated).
• Key indicators: patient or user volumes, repeat usage, gross margin, clinical outcomes and cost of acquiring each customer.
• Funding position: Whether alveofit can reach its next milestone before needing new capital.
• Regulation: Changes from the CDSCO, state health regulators, the National Medical Commission and the Digital Personal Data Protection Act.

Industry Context: Where alveofit Fits

India's healthcare market combines a large public system, a fast-growing private hospital sector and an increasingly digital layer. Government initiatives such as Ayushman Bharat and the Ayushman Bharat Digital Mission aim to widen insurance cover and create common digital health records, while telemedicine guidelines and the Digital Personal Data Protection Act shape how digital care and patient data can be used.

Demand is driven by chronic and lifestyle disease, an ageing population, rising insurance penetration and consumers who now expect to book, pay and consult online. Startups in this field compete on trust, clinical quality and convenience, and they must prove outcomes and safety as well as growth.

For readers new to this field, a useful habit is to separate announcements from evidence. A plan, a partnership or a funding headline describes intent, while a delivered product, a paying customer or an audited financial statement describes results. Comparing the two over time shows how reliably a company turns promises into outcomes.

Bull Case and Bear Case for alveofit

An investment thesis is a short, testable statement of why a company could become far more valuable, together with what evidence would prove it wrong. The points below are general to this sector and are not forecasts for alveofit.

Bull case

• Rising insurance cover and digital adoption expand the customer base.
• Strong clinical evidence builds trust with doctors and hospitals.
• Scale can improve unit economics in diagnostics and care delivery.

Bear case

• Regulatory changes can alter permitted products or business models.
• Customer acquisition costs can erode margins.
• A single safety or privacy incident can damage trust.

Lessons Founders and Investors Can Take from alveofit

Studying a company in the Respiratory care healthtech space offers lessons that go beyond any single firm. The points below are general lessons for the sector and are not claims about alveofit.

• Trust is the real currency in healthcare, so quality control, clinical evidence and data protection must be built in from the start.
• Distribution through hospitals, clinics, insurers or employers can matter more than a standalone consumer app.
• Unit economics improve when repeat usage replaces expensive one-time customer acquisition.
• Regulatory approvals can take time, so timelines and cash planning should allow for them.
• Integration with existing hospital, lab and records systems reduces friction for adoption.

How to Evaluate alveofit as a Startup

• Customer clarity: Can alveofit name its customer and the problem it solves in one sentence?
• Evidence of demand: Look for repeat customers, signed contracts or measurable usage rather than announcements alone.
• Economics: Check whether margins improve as volume grows.
• Execution: Compare announced timelines with what has actually been delivered.
• Funding runway: Estimate how long current capital lasts at the present spending rate.
• Regulatory standing: Confirm required approvals are in place.
• Customer concentration: Check whether a few customers account for most of the revenue.
• Management depth: Look for experienced leaders beyond the founders and a stable core team.

The Takeaway

alveofit is part of India’s growing Respiratory care healthtech ecosystem. The useful lesson from studying it is the discipline of asking structured questions about customers, economics, advantage and resilience. Companies that answer them well, repeatedly and under pressure are the ones that endure. Readers should treat any single report, ranking or funding headline as one input among many, and should re-check key facts against recent company announcements. Because public information on young companies is often limited, patience in verifying claims is part of good analysis. This article is educational and is not investment advice.

• Clear customers and repeat demand matter more than announcements.
• Regulation and capital needs shape how fast a startup in this sector can grow.
• Track a few leading indicators over time rather than one headline metric.

alveofit FAQs: Frequently Asked Questions

What is alveofit?

alveofit is a healthtech startup based in Pune, India, that offers a technology-enabled ecosystem for accessible and affordable respiratory care. It is profiled in the Startup Deep Dive series, which explains business model, funding, competitors and risks.

Who founded alveofit?

alveofit was founded by Devendra Prasad, Prashant Patel, and the company reports a founding year of 2019.

How much funding has alveofit raised?

$200K angel round (one database); another lists about $274K across 2 rounds including a small April 2022 round (reports differ). Funding figures are reported and may differ between sources, so readers should check the latest company announcements.

How does alveofit make money?

alveofit earns revenue from its Respiratory care healthtech products and services sold to patients, doctors, hospitals, diagnostic centres, insurers and employers. The exact revenue mix is described in the business model section and is not fully disclosed publicly.

Who are the competitors of alveofit?

Reported rivals include Aluna, AioCare, Biometry, Smart Respiratory. See the competitor comparison above for how they differ.

What are the main risks for alveofit?

Main risks include medical devices, diagnostics, online pharmacy and telemedicine each face different and changing rules, funding and capital needs, competition and regulation by the CDSCO, state health regulators, the National Medical Commission and the Digital Personal Data Protection Act. This is educational content, not investment advice.

Related Startup Deep Dives: Pathkind Labs — Pathkind: Mankind Pharma-promoted lab chain with 75+ labs | EtherealX — Bengaluru startup building a fully reusable rocket. Browse the full Startup Deep Dive series.

Source

Source: Publicly available data, published reports, industry research, and other credible sources.